Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis
- PMID: 39096115
- DOI: 10.1002/ajh.27450
Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
